Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Flu vaccines protect children well across Europe, but H3N2 remains harder to stop

8

Apr 2026

Flu vaccines protect children well across Europe, but H3N2 remains harder to stop

Influenza vaccination provided strong real-world protection for children in European primary care across two seasons, with overall vaccine effectiveness of 68% in 2022–2023 and 71% in 2023–2024. Protection was highest against influenza B and H1N1, while H3N2 showed lower and more variable effectiveness, supporting the need for higher uptake and continued monitoring.

Sponge and sea slug partnership yields a new anticancer molecule with drug design promise

8

Apr 2026

Sponge and sea slug partnership yields a new anticancer molecule with drug design promise

Researchers identified jorumycidine, a new hexacyclic marine alkaloid from the nudibranch Jorunna funebris and its dietary sponge, Haliclona sp., and demonstrated that it exhibits potent nanomolar cytotoxicity against multiple myeloma cells. They also proposed a new biosynthetic route involving cross-species metabolic interplay and an unusual oxazolidine ring that may help stabilize a pharmacologically important scaffold.

Cola may quickly lower pH inside orthodontic clear aligners and shift oral bacteria within hours

8

Apr 2026

Cola may quickly lower pH inside orthodontic clear aligners and shift oral bacteria within hours

Researchers found that cola exposure quickly lowered pH and altered the microbiome on the inner surface of clear aligners, with the greatest disruption observed when aligners were removed before drinking and then reinserted. In this small 24-hour study, wearing aligners during exposure appeared less disruptive than removing them, though the authors said the mechanism still needs further study.

Why early-onset cancers are rising and how researchers plan to stop them

8

Apr 2026

Why early-onset cancers are rising and how researchers plan to stop them

Early-onset cancers are rising worldwide, and this Cell Perspective argues that cancer prevention must move beyond static risk-factor snapshots toward life-course exposure mapping, tissue-level biology, and dynamic estimates of preventability. The authors propose three linked frameworks to speed discovery of cancer causes and translate those findings into more precise prevention and interception strategies.

New steerable optical fiber reaches previously inaccessible larynx tumors

8

Apr 2026

New steerable optical fiber reaches previously inaccessible larynx tumors

Worcester Polytechnic Institute (WPI) researchers have developed a flexible optical fiber that can be threaded through a medical endoscope and steered into the larynx to destroy hard-to-reach tumors on the vocal folds, an advance that could expand outpatient laser treatment options for patients whose only other choice might be surgery under general anesthesia.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.